PMID- 19079334
OWN - NLM
STAT- MEDLINE
DCOM- 20090629
LR  - 20230203
IS  - 1935-3456 (Electronic)
IS  - 1933-0219 (Print)
IS  - 1933-0219 (Linking)
VI  - 2
IP  - 1
DP  - 2009 Jan
TI  - Suppression of allergic airway inflammation and IgE responses by a class I 
      restricted allergen peptide vaccine.
PG  - 54-62
LID - 10.1038/mi.2008.69 [doi]
AB  - CD8 T cells are known to deviate CD4 T-cell responses from Th2 toward Th1. 
      Reduction of Th2 cytokines and increased interferon-gamma ameliorates allergic 
      airway disease. We have developed a novel approach to the suppression of allergic 
      airway inflammation, by designing a MHC class I-restricted allergen peptide 
      vaccine, which induces potent and long-lived CD8 T-cell responses. Vaccination of 
      C57BL/6 mice before allergen sensitization completely prevented allergen-specific 
      immunoglobulin E (IgE) antibody responses. Vaccination after sensitization failed 
      to suppress IgE, but inhibited accumulation of eosinophils and neutrophils in 
      airways after subsequent allergen challenge. Vaccination suppressed Th2 airway 
      infiltration and enhanced the lung Th1 response without inducing excessive CD8 
      cellular infiltration or interleukin-17, and the combination of class I peptide 
      with adjuvant was more effective than adjuvant alone. Airway hyperreactivity was 
      prevented by vaccination in an allergen-specific fashion. Class I peptide 
      vaccines might therefore represent a robust and long-lasting immunotherapeutic 
      strategy in allergic disease.
FAU - Wells, J W
AU  - Wells JW
AD  - King's College London, MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, 
      Guy's Hospital, London, UK.
FAU - Choy, K
AU  - Choy K
FAU - Lloyd, C M
AU  - Lloyd CM
FAU - Noble, A
AU  - Noble A
LA  - eng
GR  - 057704/WT_/Wellcome Trust/United Kingdom
GR  - 087618/WT_/Wellcome Trust/United Kingdom
GR  - MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081029
PL  - United States
TA  - Mucosal Immunol
JT  - Mucosal immunology
JID - 101299742
RN  - 0 (Allergens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Vaccines, Subunit)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens/*immunology
MH  - Animals
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - *Desensitization, Immunologic
MH  - Disease Models, Animal
MH  - Eosinophils/immunology
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Immunoglobulin E/*immunology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Respiratory Hypersensitivity/*immunology/pathology/*prevention & control
MH  - Th1 Cells/immunology
MH  - Th2 Cells/immunology
MH  - Vaccines, Subunit/*immunology
PMC - PMC3385352
MID - UKMS30494
OID - NLM: UKMS30494
EDAT- 2008/12/17 09:00
MHDA- 2009/06/30 09:00
PMCR- 2012/06/28
CRDT- 2008/12/17 09:00
PHST- 2008/12/17 09:00 [entrez]
PHST- 2008/12/17 09:00 [pubmed]
PHST- 2009/06/30 09:00 [medline]
PHST- 2012/06/28 00:00 [pmc-release]
AID - S1933-0219(22)01518-5 [pii]
AID - 10.1038/mi.2008.69 [doi]
PST - ppublish
SO  - Mucosal Immunol. 2009 Jan;2(1):54-62. doi: 10.1038/mi.2008.69. Epub 2008 Oct 29.